At $1.77.. But I think it is a little ahead of itself.. I know there will be a few that call me names and call me short, which is far from the truth..I think GALE's future is extremely bright, but I think we will see at least 1 if not 2 more offerings before we even get close to NDA with FDA... I have made bundles in other bios, MNKD being my most recent, and I called the same thing on them... I bought down low after an offering and killed it.. Check my previous posts.. No Monday morning QB .. Buys posted real time to show when I back up the truck... I love GALE at $1.75-1.90, and although I love gains, I am betting we will pull back below $2 well before we make our big run.. This is my $.02 and I am putting my money where my mouth is.. Remember this post....
These bashers are a joke..baseless bashes always make me laugh.
We have about 10-15% downside on potential upcoming offering, at which point I will add to my position in a big way... I knew this wins coming months ago.. This is how clinical stage Pharma works...
I will be post as I buy in the 1.70s and 1.80s.
If u are long, I would just ride it out and average down when I get the chance.. If u are short u better cover on next dip, because next run takes us to $3 aft offering.. May be 6 months or more to get thee but I am willing to wait for 80%+ or more..
la_lost - you will see Galena file a 424B5 or "prospectus" or "offer document" which is required by and filed with the Securities and Exchange Commission before they have an offering. I agree that there will be an offering just not sure when. I am thinking they will have an offering when they release substantial news such as enrollment completion or interim results. They have plenty of $ right now so they do not need to pull the trigger just yet.
Post April 22nd.... Since shelf filing has done what I expected.. Offering is almost a certainty..
Been in the game for a long while.. This is such a common pattern with clinical stage Pharma it is almost like clockwork... Will be loading up at $1.75-1.90..
If GALE gets to a much higher price with Abstral. Another offering is probably a good thing. You cannot ever have too much money in biotech land. Good examples of this would be Seattle Genetics, and more recently Celldex.
I like your style, LA: as a matter of philosophical jousting, and of "posting" our respective differences of opinions, i'll go out on the opposing limb. GALE will touch upon $2.80, never having visited $2. And after $2.80, we'll be clear to pass through $3. Several factors upon which i'm relying in viewing my crystal ball: Continued institutional buying; continued analysts recognitions of GALE; continued build of Momentum and Awareness surrounding NeuVax; viable possibilities of announced partnership/s, establishment of sales & marketing, and Ph3 participation numbers; looming possibility of news regarding Ph3 overall progress. Finally, and with all due respect, MNKD is quite an old and a tired dog. Don't get me wrong, i'm sitting on more than 100 MNKD "in-the-money" options at close to 3x my purchase price. But i dare not categorize a potential GALE spark as being anything less than HUGE as compared with the MNKD grind that we've been witness to for Years. So please put my $.02 worth of foolishness right next to yours and we'll tip a pint to the one who ends up most on target. In all other respects, be well and Profitable. Dan